Immunotherapy Combination in HER2-Positive Breast Cancer

Kevin Kalinsky, MD, MS

Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.

Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.

In patients that were PD-L1 positive, there was a significant difference in overall survival compared to PD-L1-negative patients. Kalinsky says that this poses the question of whether there is a small amount of patients that really respond to immunotherapy in this population.

Kalinsky also noted that it was interesting to see higher rates of stromal tumor-infiltrating lymphocytes in the PD-L1-positive cohort, where these lymphocytes seemed to be able to dichotomize those that would respond.